Archives
-
EX 527: Source-Bounded SIRT1 Overview
2026-10-20
EX 527, also called SEN0014196, is described by APExBIO as a racemic, selective small-molecule inhibitor of SIRT1 catalytic activity. The supplied evidence supports a focused interpretation of SIRT1-dependent deacetylation and p53 acetylation, but not broad conclusions about disease mechanisms or therapeutic effects.
-
Entinostat and HDAC-Dependent Axolotl Regeneration
2026-10-19
A study in axolotls linked nerve-dependent HDAC1 expression to blastema formation and showed that MS-275 delayed or inhibited limb regeneration without preventing initial wound closure. The findings support a stage-specific role for class I HDAC activity, while leaving unresolved which HDAC isoforms, transcriptional programs, and cell populations mediate the effect.
-
EX 527: Mechanism and Evidence Boundaries
2026-10-19
A source-grounded overview of EX 527 (SEN0014196) as a reported SIRT1 catalytic-activity inhibitor, distinguishing biochemical measurements and p53-acetylation readouts from broader claims about disease biology or therapeutic effect.
-
Netarsudil (AR-13324): Why Context Changes Results
2026-10-18
The reported behavior of Netarsudil changes meaningfully across a chemical screen, a drug-rich nanoparticle, and an immortalized trabecular meshwork cell model. Slaughter and colleagues’ findings support an in-vitro codelivery proof of concept, but they do not establish ocular delivery, aqueous humor outflow regulation, therapeutic synergy, or clinical benefit.
-
Context Changes the Meaning of EPZ-6438 Results
2026-10-17
Results obtained with EPZ-6438 acquire different meanings depending on whether the context is a biochemical assay, a cervical cancer cell model, a tissue-like assay, or a vendor-described lymphoma model. The 2025 cervical cancer study supports a context-specific preclinical signal, but its findings do not by themselves establish clinical benefit, HPV selectivity, or superiority to cisplatin.
-
Entinostat, HDAC1, and Axolotl Limb Regeneration
2026-10-16
Wang et al. reported that nerve-associated HDAC1 expression accompanied blastema formation and that pharmacological inhibition of class I HDAC activity delayed or impaired axolotl limb regeneration. The study provides convergent anatomical, molecular, pharmacological, and denervation evidence for an important role of HDAC activity, while stopping short of proving that HDAC1 alone is the direct causal effector or that findings transfer to oncology or human regeneration.
-
Entinostat and Nerve-Dependent Axolotl Regeneration
2026-10-16
Wang et al. reported that nerve-associated HDAC1 expression was temporally and spatially linked to axolotl limb regeneration, while pharmacological HDAC inhibition delayed regeneration and impaired blastema formation. The evidence supports a role for HDAC-sensitive activity in regeneration, but does not establish HDAC1 as the sole molecular target or prove that a commercial Entinostat formulation was used. Denervation, inhibitor selectivity, incomplete pharmacodynamic suppression, and species-specific biology limit extrapolation to cancer research or human tissue regeneration.
-
NAD+: Identity, Mechanism, and Evidence Boundaries
2026-10-15
A source-grounded overview of APExBIO’s NAD+ product description, covering molecular identity, redox and enzyme-related mechanisms, interpretation of NAD+ measurements, reported physicochemical properties, and the limits of the available evidence.
-
Medroxyprogesterone Acetate: Evidence and Scope
2026-10-15
Medroxyprogesterone acetate (MPA) is described by APExBIO as a synthetic steroidal progestin whose principal activity involves progesterone-receptor signaling, with additional receptor-independent effects linked in the product description to glucocorticoid-receptor binding. The same source reports renal epithelial gene-expression findings and neurobehavioral observations in aged ovariectomized rats, but provides no identity-matched paper, study-level statistics, or methodological detail. These claims therefore support a documented product and mechanism overview, not an independent assessment of efficacy, causality, or clinical applicability.
-
NAD+ and Cellular Stress: What the Evidence Shows
2026-10-14
The supplied breast-cancer study provides evidence about caspase-dependent stress adaptation, not about NAD+ itself. This overview separates the biochemical context of NAD+ from the study’s actual findings and outlines the evidence quality, uncertainties and limits on applying the results to other cells or to human treatment.
-
QPRT, P2Y11 Signaling, and Breast Cancer Invasion
2026-10-13
A 2021 study linked elevated QPRT with breast cancer invasiveness and reported that pharmacologic disruption of P2Y11-associated signaling reduced QPRT-related myosin light-chain phosphorylation and invasive behavior. The evidence supports a mechanistic association, but does not establish that P2Y11 is the sole or clinically validated mediator.
-
Entinostat and HDAC Signaling in Regeneration
2026-10-13
Entinostat, also known as MS-275, is a class I HDAC inhibitor studied in oncology and developmental biology. A 2019 axolotl study linked nerve-dependent HDAC1 expression with blastema formation and limb regeneration, while pharmacologic HDAC inhibition delayed or impaired regeneration. These findings support a role for HDAC activity in axolotl regeneration but do not establish that Entinostat can promote human tissue regeneration or predict cancer treatment outcomes.
-
SIRT1, Bone–Vascular Coupling, and Aging
2026-10-12
A preclinical study links reduced SIRT1 activity with impaired vascular and osteogenic function in aging bone, while identifying β-catenin/Wnt signaling as a possible mediator. The findings support a mechanistic hypothesis for skeletal regeneration but do not establish human efficacy, safety, or the use of any specific commercial product.
-
M344: Evidence, Context, and Key Limitations
2026-10-12
M344 is described by APExBIO as a cell-permeable histone deacetylase inhibitor with reported activity across several cellular and ex vivo research models. The available supplied evidence is primarily a product description rather than a fully documented primary study, while the cited degarelix article is unrelated and cannot substantiate claims about M344. Accordingly, reported effects should be treated as preliminary, model-specific observations rather than evidence of clinical efficacy.
-
ERK5, ERK1/2, and Vitamin D–Driven AML Differentiation
2026-10-10
Wang et al. distinguish the roles of ERK5 and ERK1/2 signaling in 1α,25-dihydroxyvitamin D3-induced differentiation of acute myeloid leukemia cells. Their findings connect ERK5 inhibition with altered myeloid marker expression and cell-cycle arrest, while showing that MEK1/2 inhibition produces a broader suppression of differentiation markers.